These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 12577855)
1. [Use of tanakan in disturbances of memory and attention in the elderly]. Zakharov VV Ter Arkh; 2002; 74(12):95-100. PubMed ID: 12577855 [No Abstract] [Full Text] [Related]
3. [Cerebral insufficiency--treatment with Ginkgo-biloba extract. Time of onset of effect in a double-blind study with 60 inpatients]. Eckmann F Fortschr Med; 1990 Oct; 108(29):557-60. PubMed ID: 2242846 [TBL] [Abstract][Full Text] [Related]
4. Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial. Shakibaei F; Radmanesh M; Salari E; Mahaki B Complement Ther Clin Pract; 2015 May; 21(2):61-7. PubMed ID: 25925875 [TBL] [Abstract][Full Text] [Related]
5. [How to correctly use herbs]. Bonaccorsi A Assist Inferm Ric; 2007; 26(4):219-26. PubMed ID: 18297986 [No Abstract] [Full Text] [Related]
8. A double-blind, placebo controlled study of Ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment. Rai GS; Shovlin C; Wesnes KA Curr Med Res Opin; 1991; 12(6):350-5. PubMed ID: 2044394 [TBL] [Abstract][Full Text] [Related]
9. [The effect of tanakan on central nervous system function in patients with the residual manifestations of stroke]. Kuznetsova SM; Glazovskaia II; Kuznetsov VV Lik Sprava; 1997; (6):132-4. PubMed ID: 9589957 [No Abstract] [Full Text] [Related]
11. Ginkgo and Alzheimer's disease: little or no different from placebo. Prescrire Int; 2007 Oct; 16(91):205-7. PubMed ID: 17926840 [TBL] [Abstract][Full Text] [Related]
12. [Effect of tanakan on psychophysiological status of patients with asthenic disorders]. Neznamov GG; Teleshova ES; Siuniakov SA; Morozov IS; Davydova IA; Zhirnov EN Eksp Klin Farmakol; 2002; 65(1):19-23. PubMed ID: 12025777 [TBL] [Abstract][Full Text] [Related]
13. [Tanakan as a multimodal cytoprotective factor in general medicine]. Naprienko MV; Esin RG; Mukhametova ER; Esin OR; Smekalkina LV Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(11):146-151. PubMed ID: 27030838 [TBL] [Abstract][Full Text] [Related]
14. [Experience in clinical use of tanakan in the treatment of the syndrome of mild cognitive impairment]. Gavrilova SI; Fedorova IaB; Roshchina IF; Kolykhalov IV Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(10):42-6. PubMed ID: 17117673 [TBL] [Abstract][Full Text] [Related]
15. Conflicting results on ginkgo research. Le Bars P Forsch Komplementarmed Klass Naturheilkd; 2002 Feb; 9(1):19-20. PubMed ID: 11968151 [No Abstract] [Full Text] [Related]
17. Vasodilators and nootropics as predictors of dementia and mortality in the PAQUID cohort. Dartigues JF; Carcaillon L; Helmer C; Lechevallier N; Lafuma A; Khoshnood B J Am Geriatr Soc; 2007 Mar; 55(3):395-9. PubMed ID: 17341242 [TBL] [Abstract][Full Text] [Related]
18. [Statement to the preliminary report of the IQWiG A05-19B ginkgo-containing preparation at Alzheimers dementia]. Gogol M; Lüttje D; Sieber C; Werner H Z Gerontol Geriatr; 2007 Aug; 40(4):282-4. PubMed ID: 17701119 [No Abstract] [Full Text] [Related]
19. Ginkgo might not be a brain saver. Consum Rep; 2009 Mar; 74(3):14. PubMed ID: 19309768 [No Abstract] [Full Text] [Related]
20. Ginkgo and AD: key negatives and lessons from GuidAge. Schneider LS Lancet Neurol; 2012 Oct; 11(10):836-7. PubMed ID: 22959218 [No Abstract] [Full Text] [Related] [Next] [New Search]